Human iPS cell-based therapy: Considerations before clinical applications

99Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Generation of induced pluripotent stem (iPS) cells has revolutionized the field of regenerative medicine. with the exponential increase in iPS cell research in the past three years, human iPS cells have been derived with different technologies and from various cell types. From a translational perspective, however, a number of issues must be addressed before safe and high quality patient-specific iPS cells can be derived for clinical applications. In addition, iPS cell-based therapies also need to be thoroughly evaluated in pre-clinical animal models before they can be applied to human subjects. © 2010 Landes Bioscience.

Cite

CITATION STYLE

APA

Sun, N., Longaker, M. T., & Wu, J. C. (2010, March 1). Human iPS cell-based therapy: Considerations before clinical applications. Cell Cycle. Taylor and Francis Inc. https://doi.org/10.4161/cc.9.5.10827

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free